Enhertu — trastuzumab deruxtecan
Named-patient access overview. Enhertu is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Enhertu
Enhertu (trastuzumab deruxtecan) is manufactured by Daiichi/AZ and indicated for HER2 solid tumors. It is a HER2 ADC approved by the US FDA in 2019 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Enhertu
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Enhertu for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Enhertu is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
We have documented named-patient access pathways for Enhertu in the countries below. Each page outlines the destination-country regulatory posture, typical timeline, and physician-credential requirements.
Enhertu in BangladeshNamed-patient access, timeline, and regulatory notes
Enhertu in IndiaNamed-patient access, timeline, and regulatory notes
Enhertu in NepalNamed-patient access, timeline, and regulatory notes
Enhertu in OmanNamed-patient access, timeline, and regulatory notes
Enhertu in PakistanNamed-patient access, timeline, and regulatory notes
Enhertu in Sri LankaNamed-patient access, timeline, and regulatory notes
Enhertu in TurkeyNamed-patient access, timeline, and regulatory notes
Enhertu in United Arab EmiratesNamed-patient access, timeline, and regulatory notes
Start a request for Enhertu
Submit a 60-second intake. Our clinical team responds within one business day with case-specific feasibility, timeline, and a formal quote.